Who are FLU-v's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qiv, Trivalent Inactivated Vaccine, Quadrivalent Influenza Vaccine, Seasonal Inactivated Influenza Vaccine, GamEvac-Combi (vaccine), DTacP-IPV combined vaccine (TETRAXIM™).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flu-v.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FLU-v — Competitive Intelligence Brief

FLU-v (FLU-v) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated vaccine. Area: Infectious Diseases.

phase 2 inactivated vaccine Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

FLU-v (FLU-v) — PepTcell Limited. FLU-v is an inactivated influenza vaccine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FLU-v TARGET	FLU-v	PepTcell Limited	phase 2	inactivated vaccine
Qiv	qiv	Pfizer	marketed	Inactivated vaccine	Influenza viruses
Trivalent Inactivated Vaccine	Trivalent Inactivated Vaccine	McMaster University	marketed	Inactivated vaccine
Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine	International Centre for Diarrhoeal Disease Research, Bangladesh	marketed	Inactivated vaccine	Influenza viruses
Seasonal Inactivated Influenza Vaccine	Seasonal Inactivated Influenza Vaccine	Pfizer	marketed	Inactivated vaccine
GamEvac-Combi (vaccine)	GamEvac-Combi (vaccine)	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	marketed	Combination inactivated vaccine
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated vaccine class)

Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Hoffmann-La Roche · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
PepTcell Limited · 1 drug in this class
Seqirus · 1 drug in this class
Sinovac Biotech Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FLU-v — Competitive Intelligence Brief. https://druglandscape.com/ci/flu-v. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab